URGN

UroGen is a just-turned-commercial uro-oncology biotech, not a stable cash generator, and the call hinges on whether the June 12, 2025 FDA approval of Zusduri converts into a durable second product. The top line is genuinely encouraging: revenue grew to $110M (+21.4%), the fifth straight year of acceleration (48→64→83→90→110M), at an 88.7% gross margin — economics that, if Zusduri scales into the cited ~$5B recurrent low-grade intermediate-risk NMIBC market as the 'first and only FDA-approved non-surgical treatment,' could re-rate the equity. Jelmyto plus Zusduri give two approved RTGel products and a real, growing revenue base behind the story.

But the balance sheet and cash dynamics are the problem the bull case has to outrun. Operating income was -$125M (-113.7% margin), net loss widened to -$153M, and operating cash flow deteriorated to -$162M against just $111M of cash (down 35.6%). Stockholders' equity is negative (-$105M) on a -$960M accumulated deficit, so liabilities/equity is a meaningless -2.90x — this company funds itself with debt and stock, not earnings. The 10-K is explicit: 'We will require additional financing... a failure to obtain this capital... could force us to delay, limit, reduce or terminate' operations. The February 2026 Pharmakon refinancing ($200M first tranche at a fixed 8.25%, secured by substantially all assets including IP, plus a $50M option) extends runway and removes the near-term cliff, but it is expensive, senior, and collateralized — and principal repayment begins Q1 2030, so the launch must work before then.